We are live on
!
Find out more
LP
LMR Partners Portfolio holdings
AUM
$45.4B
1-Year Est. Return
60.68%
This Fund
S&P 500
This Quarter
Est. Return
+23.27%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$11.9B
AUM Growth
-$665M
(-5.3%)
Cap. Flow
-$2.07B
Cap. Flow
% of AUM
-17.42%
Top 10 Holdings %
Top 10 Hldgs %
29.25%
Holding
1,790
New
534
Increased
200
Reduced
243
Closed
613
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$472M |
| 2 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
+$63M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$61M |
| 4 |
FYBR
Frontier Communications
FYBR
|
+$56.7M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$107M |
| 2 |
GSK
GSK
|
+$58.9M |
| 3 |
Broadcom
AVGO
|
+$54M |
| 4 |
Unilever
UL
|
+$54M |
| 5 |
Marvell Technology
MRVL
|
+$48.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.5% |
| 2 | Communication Services | 3.61% |
| 3 | Financials | 3.6% |
| 4 | Healthcare | 3.01% |
| 5 | Consumer Discretionary | 1.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
PUT
Boston Scientific
BSX
$70B
| $44.7K | ﹤0.01% |
500
-38,500
| -99% | -$3.39M |
|
|
PROCW
1002
DELISTED
Procaps Group, S.A. Warrants
PROCW
| $44.3K | ﹤0.01% |
+1,059,854
| New | +$26.7K |
|
1003
EUDA Health Holdings Warrant
EUDAW
$218K
| $44.3K | ﹤0.01% |
+300,000
| New | +$30.1K |
|
|
LFLYW
1004
DELISTED
Leafly Holdings, Inc. Warrant
LFLYW
| $41.9K | ﹤0.01% |
+2,329,972
| New | +$67.1K |
|
1005
PUT
Insmed
INSM
$22.7B
| $41.4K | ﹤0.01% |
+600
| New | +$43.2K |
|
1006
SAB Biotherapeutics Warrant
SABSW
$71.5K
| $40.6K | ﹤0.01% |
+539,588
| New | +$32.5K |
|
|
1007
CALL
Vertex Pharmaceuticals
VRTX
$125B
| $40.3K | ﹤0.01% |
+100
| New | +$46.4K |
|
|
LMND.WS
1008
DELISTED
Lemonade Inc Warrants
LMND.WS
| $39.6K | ﹤0.01% |
+290,978
| New | +$27.4K |
|
1009
CALL
AMC Entertainment Holdings
AMC
$2.27B
| $35.8K | ﹤0.01% |
9,000
-1,149,700
| -99% | -$5.05M |
|
1010
Truist Financial
TFC
$64.5B
| $35.2K | ﹤0.01% |
812
+792
| +3,960% | +$35.3K |
|
|
SBXD.WS
1011
SilverBox Corp IV Warrants
SBXD.WS
| $35K | ﹤0.01% |
+166,666
| New | +$27.6K |
|
1012
AT&T
T
$173B
| $34.9K | ﹤0.01% |
+1,533
| New | +$34.5K |
|
1013
Evergy
EVRG
$20.1B
| $32.7K | ﹤0.01% |
+532
| New | +$32.9K |
|
|
K
1014
PUT
DELISTED
Kellanova
K
| $32.4K | ﹤0.01% |
400
-100,000
| -100% | -$8.08M |
|
1015
Abercrombie & Fitch
ANF
$4.57B
| $31.2K | ﹤0.01% |
209
-441
| -68% | -$64.4K |
|
1016
P3 Health Partners Inc Warrant
PIIIW
$135K
| $30.3K | ﹤0.01% |
+2,546,924
| New | +$47.1K |
|
1017
RTX Corp
RTX
$298B
| $30.2K | ﹤0.01% |
+261
| New | +$31.5K |
|
1018
PPG Industries
PPG
$27.5B
| $30K | ﹤0.01% |
251
-2,064
| -89% | -$258K |
|
|
GWH.WS
1019
DELISTED
ESS Tech Inc Warrant
GWH.WS
| $29.3K | ﹤0.01% |
+451,284
| New | +$26K |
|
|
VXRT
1020
DELISTED
Vaxart
VXRT
| $28.5K | ﹤0.01% |
43,081
| – | – |
|
1021
CALL
VanEck Gold Miners ETF
GDX
$22.5B
| $27.1K | ﹤0.01% |
800
-484,200
| -100% | -$18.6M |
|
|
1022
PUT
VanEck Gold Miners ETF
GDX
$22.5B
| $27.1K | ﹤0.01% |
800
-489,300
| -100% | -$18.8M |
|
1023
AEON Biopharma
AEON
$11M
| $26.4K | ﹤0.01% |
679
| – | – |
|
1024
Alliant Energy
LNT
$19.4B
| $26K | ﹤0.01% |
440
-2,442
| -85% | -$148K |
|
1025
Halliburton
HAL
$26.5B
| $26K | ﹤0.01% |
957
-11,422
| -92% | -$334K |
|
Similar funds
AS
TI
LMR Partners's Q4 2024 Portfolio in Review
As of Q4 2024, LMR Partners held 1,790 positions worth $11.9B, down 5.3% from $12.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
LMR Partners withdrew a net $2.07B in Q4 2024, closing 613 positions and reducing 243 holdings. Its most notable exit was Unilever, an estimated $54M position sold in full.
By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 10% a quarter earlier, followed by Communication Services and Financials.
Against the trend, LMR Partners opened a new position in Vertex Pharmaceuticals worth $37.8M.
- LMR Partners's largest Q4 2024 buy was Vertex Pharmaceuticals: 93,801 shares worth $37.8M.
- LMR Partners added most to State Street SPDR S&P 500 ETF Trust in Q4 2024, an estimated $472M increase.
- LMR Partners's biggest Q4 2024 reduction was TSMC, cutting an estimated $107M.
- LMR Partners fully exited Unilever in Q4 2024, selling an estimated $54M.
- LMR Partners's ten largest holdings make up 29% of its $11.9B portfolio in Q4 2024.
- LMR Partners opened 534 new positions and closed 613 in Q4 2024.
- LMR Partners's portfolio value fell 5.3% quarter-over-quarter to $11.9B.
Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.